|ObsEva SA to Participate in Upcoming Investor Conferences|
|By: Nasdaq / GlobenewsWire - 16 May 2019||Back to overview list
Geneva, Switzerland and Boston, MA – May 16, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating in three upcoming investor conferences.
Conference presentations will be webcast, and available in the “Investors” section of ObsEva’s website www.ObsEva.com.
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
Media Contact Switzerland and Europe:
Media Contact U.S.:
Marion Janic RooneyPartners LLC
CEO Office Contact:
Senior Director, Investor Relations
Copyright 2019 Nasdaq / GlobenewsWire
|Back to overview list|